




The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 118% points. The greatest weakness of Spyre Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 347%, being 95% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	54,991
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,629
Liabilities, Non-Current	111
Other Assets	232
Other Compr. Net Income	-98
Other Expenses	0
Other Liabilities	0
Other Net Income	5,645
Other Revenues	0
Property and Equipment	854
Research and Development	22,815
Selling, General and Administrative Expense	10,066

Output Variable	Value in 1000 USD
Assets	56,077
Liabilities	5,740
Expenses	32,881
Revenues	0
Stockholders Equity	50,337
Net Income	-27,236
Comprehensive Net Income	-27,285
BaseVar	50,220
ECR before Limited Liability	267%
Economic Capital Ratio	347%